Key result
Moderate-dose dietary nitrate improves FMD by ~1.3% and extends maximal walking distance in PAD patients.
Why the study?
Dietary nitrate has been used to reduce blood pressure and improve walking capacity in peripheral artery disease, but a standardized dose has not been determined.
Does a body mass-normalized moderate dose of dietary nitrate improve vascular function and walking capacity in patients with peripheral artery disease?
RCT (n=11)
Double-blind
Randomized crossover
No
Does a body mass-normalized moderate dose of dietary nitrate improve vascular function and walking capacity in patients with peripheral artery disease?
A body mass-normalized moderate dose of dietary nitrate improves endothelial function, reduces blood pressure, and increases walking capacity in patients with peripheral artery disease.
Supports dietary nitrate as adjunct in PAD; extends endothelial benefits to walking capacity in this RCT.
Peripheral artery disease (PAD) is characterized by the accumulation of atherosclerotic plaques in the lower extremity conduit arteries, which impairs blood flow and walking capacity. Dietary nitrate has been used to reduce blood pressure (BP) and improve walking capacity in PAD. However, a standardized dose for PAD has not been determined. Therefore, we sought to determine the effects of a body mass-normalized moderate dose of nitrate (0.11 mmol nitrate/kg) as beetroot juice on serum nitrate/nitrite, vascular function, walking capacity, and tissue oxygen utilization capacity in patients with PAD. A total of 11 patients with PAD received either nitrate supplement or placebo in a randomized crossover design. Total serum nitrate/nitrite, resting BP, brachial and popliteal artery endothelial function (flow-mediated dilation, FMD), arterial stiffness (pulse-wave velocity, PWV), augmentation index (AIx), maximal walking distance and time, claudication onset time, and skeletal muscle oxygen utilization were measured pre- and postnitrate and placebo intake. There were significant group × time interactions ( P < 0.05) for serum nitrate/nitrite, FMD, BP, walking distance and time, and skeletal muscle oxygen utilization. The nitrate group showed significantly increased serum nitrate/nitrite (Δ1.32 μM), increased brachial and popliteal FMD (Δ1.3% and Δ1.7%, respectively), reduced peripheral and central systolic BP (Δ−4.7 mmHg and Δ−8.2 mmHg, respectively), increased maximal walking distance (Δ92.7 m) and time (Δ56.3 s), and reduced deoxygenated hemoglobin during walking. There were no changes in PWV, AIx, or claudication ( P > 0.05). These results indicate that a body-mass normalized moderate dose of nitrate may be effective and safe for reducing BP, improving endothelial function, and improving walking capacity in patients with PAD.
No takes yet. Share an insight, caveat, or question.
Pekas et al. (2021) conducted an RCT in Peripheral artery disease (PAD) (n=11). Dietary nitrate (beetroot juice) vs. Nitrate-void placebo (tapioca powder capsules) was evaluated on Brachial artery flow-mediated dilation (FMD) (Δ1.3%, p=<0.01). A body mass-normalized moderate dose of dietary nitrate significantly increased brachial flow-mediated dilation by 1.3% and maximal walking distance by 92.7 m compared to placebo in patients with PAD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: